Skip to main content

Infantile Hemangioma

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
propranolol gelPHASE_21 trial
PropranololPHASE_2_3Small Molecule1 trial
Active Trials
NCT01512173Completed82Est. May 2013
NCT01056341Completed512Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pierre FabrePropranolol
Pierre Fabrepropranolol gel

Clinical Trials (2)

Total enrollment: 594 patients across 2 trials

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Start: Jan 2010Est. completion: Nov 2013512 patients
Phase 2/3Completed

Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo

Start: Jan 2012Est. completion: May 201382 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.